查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362982

iPS細胞（誘導性多功能幹細胞）市場規模、佔有率和趨勢分析報告：按衍生細胞類型、應用、最終用途、地區和細分市場預測，2023-2030年

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

iPS細胞（誘導性多功能幹細胞）市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球iPS細胞市場規模將達到30.9億美元，2023年至2030年年複合成長率為10.61%。

iPS 細胞 (iPSC) 市場迅速擴大。其使用的主要原因是iPS細胞可以生成人體必需的所有細胞和組織，以對抗和對抗白血病、脊髓損傷、心血管疾病和糖尿病等疾病。

推動市場擴張的其他因素包括研究支出的增加、基因組學計劃的增加以及基因組工程在個體化治療中的應用迅速增加。因此，iPSC 的採用加速，導致市場收益成長。例如，2020年 10月，Axxam SpA 和 FUJIFILM Cellular Dynamics, Inc. 宣佈建立策略夥伴關係，以推進藥物研發過程。透過使用能夠實現標靶評估、高通量篩選 (HTS) 和高內涵篩選的尖端藥物研發技術，這項合作夥伴關係將為藥物研發研究人員和科學家提供基於 hiPSC 檢測的整合平台。去做。

近年來，醫療開發和研究的投資大幅增加，預計這一趨勢將對預測期內 iPS 細胞的需求產生重大影響。人類iPSC細胞株在精準醫療中應用範圍的擴大以及對幹細胞治療應用的日益重視預計將成為推動iPS細胞市場擴張的重要因素。例如，根據兩家公司的聯合聲明，2021年 3月，Sana Biotechnology 獲得批准使用FUJIFILM Cellular Dynamics 的 iPSC 平台來創建商業性化的細胞療法。細胞療法可以改善、修改或替代人類生物學，包括細胞、組織和器官。

COVID-19 大流行期間研究活動的活性化也促進了 iPSC 的研究。此外，科學家們不斷努力發現新治療方法和控制 SARS CoV-2 感染的治療方法，這增加了對 iPSC 作為研究工具的需求。此外，iPS 細胞可用於研究人類病毒感染的病理學，因為它們可以產生生理上等效的類器官和器官模型。因此，它支撐著產業的發展。

此外，隨著致力於與 iPS 細胞相關的各種科學活動的行業的發展，政府和商業部門日益增加資金，公眾對幹細胞的認知也透過各種組織不斷提高。然而，細胞重編程成本高、倫理問題、流程耗時等挑戰在某種程度上阻礙了iPS細胞產業的發展。此外，低效率、潛在腫瘤風險和糟糕的程式設計也是限制 iPSC 市場擴張的問題。

iPS 細胞市場報告亮點

  • 從衍生細胞類型來看，纖維母細胞區隔佔比最大，2022年為30.48%。醫學專業人士越來越偏好將成纖維母細胞作為皮膚問題的潛在治療方法，這推動該領域的發展。
  • 依應用來看，藥物研發領域佔比最大，2022年為49.09%。慢性病的流行、久坐的生活方式等日益增加對個體化治療的需求，而製藥和生物技術公司對借助 iPS 細胞開發藥物的興趣日益濃厚，推動該行業的成長。
  • 依最終用途分類，製藥和生物技術公司佔最大佔有率，2022年為59.77%。該細分市場預計將主導市場，因為它使用 iPS 細胞製造和開發針對各種疾病的各種幹細胞產品和技術。
  • 2022年，北美將佔據42.36%的較大佔有率。這主要是由於創新系統和技術在藥物研究、毒性測試和疾病建模方面的使用越來越多，而該地區對幹細胞療法的日益接受度也推動了市場的發展，這是主要因素。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系展望
  • 市場趨勢及展望
  • 市場動態
  • 市場抑制因素分析
  • 營商環境分析

第4章 衍生細胞類型的業務分析

  • 全球 iPS 細胞市場：衍生細胞類型的變異分析
  • 肝細胞
  • 纖維母細胞
  • 角質形成細胞
  • 羊膜細胞
  • 其他

第5章 商業分析的應用

  • 全球 iPS 細胞市場：應用變化分析
  • 藥物開發
  • 組織工程與再生醫學
  • 毒理學研究
  • 疾病建模

第6章 最終用戶業務分析

  • 全球 iPS 細胞市場：最終用戶波動分析
  • 學術/研究機構
  • 製藥和生物技術公司
  • 其他

第7章 區域業務分析

  • 全球 iPS 細胞市場佔有率（依地區分類，2022年和2030年）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東、非洲

第8章 競爭形勢

  • 公司分類
  • 策略規劃
  • 2022年公司市場佔有率分析
  • 公司簡介/名單
    • STEMCELL Technologies Inc.
    • Cellular Engineering Technologies Inc.
    • REPROCELL Inc.
    • Takara Bio, Inc.
    • Axol Bioscience Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Corporation（FUJIFILM Cellular Dynamics, Inc.）
    • Cynata Therapeutics Limited
    • Evotec SE
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-116-1

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.09 billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report highlights

  • By derived cell type, the fibroblasts segment accounted for the largest share of 30.48% in 2022. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
  • By application, the drug developmentsegment accounted for the largest share of 49.09% in 2022. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
  • By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.77% in 2022. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
  • North America held the larger share of 42.36% in 2022. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Europe Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increase in research and development activities in stem cells therapies
    • 3.3.2. Surge in adoption of personalized medicine
  • 3.4. Market Restraint Analysis
    • 3.4.1. Lack of awareness regarding stem cell therapies
    • 3.4.2. High cost of treatment
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Derived Cell Type Business Analysis

  • 4.1. Global induced pluripotent stem cells market: Derived Cell Type Movement Analysis
  • 4.2. Hepatocytes
    • 4.2.1. Hepatocytes Market, 2018 - 2030 (USD Million)
  • 4.3. Fibroblasts
    • 4.3.1. Fibroblasts Market, 2018 - 2030 (USD Million)
  • 4.4. Keratinocytes
    • 4.4.1. Keratinocytes Market, 2018 - 2030 (USD Million)
  • 4.5. Amniotic Cells
    • 4.5.1. Amniotic Cells Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Global induced pluripotent stem cells market: Application Movement Analysis
  • 5.2. Drug Development
    • 5.2.1. Drug Development Market, 2018 - 2030 (USD Million)
  • 5.3. Tissue Engineering & Regenerative Medicine
    • 5.3.1. Tissue Engineering & Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 5.3.2. Neurology
      • 5.3.2.1. Neurology Market, 2018 - 2030 (USD Million)
    • 5.3.3. Orthopedics
      • 5.3.3.1. Orthopedics Market, 2018 - 2030 (USD Million)
    • 5.3.4. Oncology
      • 5.3.4.1. Oncology Market, 2018 - 2030 (USD Million)
    • 5.3.5. Cardiovascular and Myocardial Infraction
      • 5.3.5.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Million)
    • 5.3.6. Diabetes
      • 5.3.6.1. Diabetes Market, 2018 - 2030 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Others Market, 2018 - 2030 (USD Million)
  • 5.4. Toxicology Research
    • 5.4.1. Toxicology Research Market, 2018 - 2030 (USD Million)
  • 5.5. Disease Modeling
    • 5.5.1. Disease Modeling Market, 2018 - 2030 (USD Million)

Chapter 6. End-User Business Analysis

  • 6.1. Global induced pluripotent stem cells market: End-User Movement Analysis
  • 6.2. Academic & Research Institutes
    • 6.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.3. Pharmaceutical & Biotechnology Companies
    • 6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Global Induced Pluripotent Stem Cells Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Target Disease Prevalence
      • 7.2.2.5. U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Target Disease Prevalence
      • 7.2.3.5. Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Induced Pluripotent Stem Cells Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Target Disease Prevalence
      • 7.3.2.5. Germany induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Target Disease Prevalence
      • 7.3.3.5. UK induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Target Disease Prevalence
      • 7.3.4.5. France induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Target Disease Prevalence
      • 7.3.5.5. Italy induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Target Disease Prevalence
      • 7.3.6.5. Spain induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Target Disease Prevalence
      • 7.3.7.5. Denmark induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Target Disease Prevalence
      • 7.3.8.5. Sweden induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Target Disease Prevalence
      • 7.3.9.5. Norway induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Target Disease Prevalence
      • 7.4.2.5. Japan induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Target Disease Prevalence
      • 7.4.3.5. China induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Target Disease Prevalence
      • 7.4.4.5. India induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Target Disease Prevalence
      • 7.4.5.5. South Korea induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Target Disease Prevalence
      • 7.4.6.5. Australia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Target Disease Prevalence
      • 7.4.7.5. Thailand induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Target Disease Prevalence
      • 7.5.2.5. Brazil induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Target Disease Prevalence
      • 7.5.3.5. Mexico induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Target Disease Prevalence
      • 7.5.4.5. Argentina induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Target Disease Prevalence
      • 7.6.2.5. South Africa induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Target Disease Prevalence
      • 7.6.3.5. Saudi Arabia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Target Disease Prevalence
      • 7.6.4.5. UAE induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Target Disease Prevalence
      • 7.6.5.5. Kuwait induced pluripotent stem cells market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2022
  • 8.4. Company Profiles/Listing
    • 8.4.1. STEMCELL Technologies Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Cellular Engineering Technologies Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. REPROCELL Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Takara Bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Axol Bioscience Ltd.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Fate Therapeutics, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. FUJIFILM Corporation (FUJIFILM Cellular Dynamics, Inc.)
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Cynata Therapeutics Limited
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Evotec SE
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Astellas Pharma Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 4 Global Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 6 North America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 7 North America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 8 North America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 9 North America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 10 U.S. Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 16 Europe Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 20 UK Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 21 UK Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 22 UK Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 26 France Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 27 France Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 28 France Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 35 Denmark Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 38 Sweden Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 41 Norway Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 48 China Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 49 China Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 50 China Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 53 Japan Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 54 India Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 55 India Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 56 India Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 63 Thailand Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 66 Latin America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 68 Latin America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 70 Brazil Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 73 Mexico Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Induced Pluripotent Stem Cells Market by End-User, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 83 South Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Induced Pluripotent Stem Cells Market By End-Use, 2018 - 2030 (USD Million)
  • Table 95 Participant's Overview
  • Table 96 Financial Performance
  • Table 97 Key Companies Undergoing Expansions
  • Table 98 Key Companies Undergoing Acquisitions
  • Table 99 Key Companies Undergoing Collaborations
  • Table 100 Key Companies Launching New Products/Services
  • Table 101 Key Companies Undergoing Partnerships
  • Table 102 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global induced pluripotent stem cells market: Derived cell type outlook and key takeaways
  • Fig. 16 Global induced pluripotent stem cells market: Derived cell type movement analysis
  • Fig. 17 Global hepatocytes market, 2018 - 2030 (USD Million)
  • Fig. 18 Global fibroblasts market, 2018 - 2030 (USD Million)
  • Fig. 19 Global keratinocytes market, 2018 - 2030 (USD Million)
  • Fig. 20 Global amniotic cells market, 2018 - 2030 (USD Million)
  • Fig. 21 Global others market, 2018 - 2030 (USD Million)
  • Fig. 22 Global induced pluripotent stem cells market: Application outlook and key takeaways
  • Fig. 23 Global induced pluripotent stem cells market: Application movement analysis
  • Fig. 24 Global drug development market, 2018 - 2030 (USD Million)
  • Fig. 25 Global tissue engineering & regenerative medicine market, 2018 - 2030 (USD Million)
  • Fig. 26 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 27 Global orthopedics market, 2018 - 2030 (USD Million)
  • Fig. 28 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cardiovascular and myocardial infraction market, 2018 - 2030 (USD Million)
  • Fig. 30 Global diabetes market, 2018 - 2030 (USD Million)
  • Fig. 31 Global others market, 2018 - 2030 (USD Million)
  • Fig. 32 Global toxicology research market, 2018 - 2030 (USD Million)
  • Fig. 33 Global disease modeling market, 2018 - 2030 (USD Million)
  • Fig. 34 Global induced pluripotent stem cells market: End-use outlook and key takeaways
  • Fig. 35 Global induced pluripotent stem cells market: End-use movement analysis
  • Fig. 36 Global academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 37 Global pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
  • Fig. 38 Global induced pluripotent stem cells market: Regional outlook and key takeaways
  • Fig. 39 North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Germany key country dynamics
  • Fig. 46 Germany induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Asia-Pacific induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 India key country dynamics
  • Fig. 65 India induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea key country dynamics
  • Fig. 67 South Korea induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Australia key country dynamics
  • Fig. 71 Australia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 MEA induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Market participant categorization
  • Fig. 91 induced pluripotent stem cells market share analysis, 2022
  • Fig. 92 Strategy framework